V体育平台登录 - Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The . gov means it’s official. Federal government websites often end in . gov or . mil VSports app下载. Before sharing sensitive information, make sure you’re on a federal government site. .

Https

The site is secure V体育官网. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely. .

. 2009 Oct 15;69(20):7905-10.
doi: 10.1158/0008-5472.CAN-09-2099. Epub 2009 Oct 13.

"V体育ios版" Direct evidence that bevacizumab, an anti-VEGF antibody, up-regulates SDF1alpha, CXCR4, CXCL6, and neuropilin 1 in tumors from patients with rectal cancer

Lei Xu  1 , Dan G Duda, Emmanuelle di Tomaso, Marek Ancukiewicz, Daniel C Chung, Gregory Y Lauwers, Rekha Samuel, Paul Shellito, Brian G Czito, Pei-Chun Lin, Martin Poleski, Rex Bentley, Jeffrey W Clark, Christopher G Willett, Rakesh K Jain
Affiliations

"V体育平台登录" Direct evidence that bevacizumab, an anti-VEGF antibody, up-regulates SDF1alpha, CXCR4, CXCL6, and neuropilin 1 in tumors from patients with rectal cancer

Lei Xu et al. Cancer Res. .

Abstract

Clinical studies converge on the observation that circulating cytokines are elevated in most cancer patients by anti-vascular endothelial growth factor (VEGF) therapy. However, the source of these molecules and their relevance in tumor escape remain unknown. We examined the gene expression profiles of cancer cells and tumor-associated macrophages in tumor biopsies before and 12 days after monotherapy with the anti-VEGF antibody bevacizumab in patients with rectal carcinoma. Bevacizumab up-regulated stromal cell-derived factor 1alpha (SDF1alpha), its receptor CXCR4, and CXCL6, and down-regulated PlGF, Ang1, and Ang2 in cancer cells. In addition, bevacizumab decreased Ang1 and induced neuropilin 1 (NRP1) expression in tumor-associated macrophages VSports手机版. Higher SDF1alpha plasma levels during bevacizumab treatment significantly associated with distant metastasis at three years. These data show that VEGF blockade up-regulates inflammatory pathways and NRP1, which should be evaluated as potential targets for improving anti-VEGF therapy. .

PubMed Disclaimer

Conflict of interest statement (V体育平台登录)

Disclosure of Potential Conflicts of Interest

B. G. Czito: commercial research grant, Genentech. C. G V体育安卓版. Willett: speaker honorarium, Genentech. R. K. Jain: commercial research grant, AstraZeneca and Dyax; consultant/advisory board, AstraZeneca, Dyax, Millennium, and SynDevRx; speaker honorarium, Pfizer. The other authors disclosed no potential conflicts of interest.

Figures (VSports手机版)

Figure 1
Figure 1
Changes in expression in cancer cells and TAMs from rectal carcinoma and in circulating plasma SDF1α levels after bevacizumab treatment. A, representative image of tumor tissue after selected tumor cells were burned by the capture laser and before RNA extraction (inset). B, selection of TAMs for LCM guided by CD68 immunostaining. Images of TAMs, burned by the capture laser of the cap containing TAMs (inset ; magnification, ×20). C, comparison of relative SDF1α and CXCR4 RNA levels in tumor cells captured by LCM from 12 pairs of serial biopsy samples collected before and 12 d after bevacizumab monotherapy. Columns, mean fold change in gene expression compared with pretreatment value. GAPDH was used as RNA control in the PCR. D, kinetics of plasma SDF1α after treatment with bevacizumab alone (day 12) and after bevacizumab with chemoradiation (day 32). Note the relatively high circulating levels of SDF1α (median of >1 ng/mL, shown with 95% confidence intervals) and the lack of consistent change in the overall population. Pre-Tx, pretreatment.
See this image and copyright information in PMC

References

    1. Jain RK, Duda DG, Willett CG, et al. Biomarkers of response and resistance to antiangiogenic therapy. Nat Rev Clin Oncol. 2009;6:327–338. - PMC - PubMed
    1. Wolmark N, Yothers G, O’Connell MG, et al. A phase III trial comparing mFOLFOX6 to mFOLFOX6 plus bevacizumab in stage II or III carcinoma of the colon: results of NSABP protocol C-08. J Clin Oncol. 2009;27 suppl abstr LBA4. - PMC (VSports手机版) - PubMed
    1. Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature. 2000;407:249–257. - VSports手机版 - PubMed
    1. Batchelor TT, Sorensen AG, di Tomaso E, et al. AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell. 2007;11:83–95. - PMC - PubMed
    1. Zhu AX, Sahani DV, Duda DG, et al. Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II study. J Clin Oncol. 2009;27:3027–3035. - PMC (V体育2025版) - PubMed

Publication types

MeSH terms